Isaac E. Ciechanover Net Worth

The estimated Net Worth of Isaac E. Ciechanover is at least $29.1 millió dollars as of 29 May 2019. Isaac Ciechanover owns over 5,850 units of Atara Biotherapeutics Inc stock worth over $2,415,609 and over the last 10 years Isaac sold ATRA stock worth over $26,733,403.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Isaac Ciechanover ATRA stock SEC Form 4 insiders trading

Isaac has made over 113 trades of the Atara Biotherapeutics Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently Isaac sold 5,850 units of ATRA stock worth $135,077 on 29 May 2019.

The largest trade Isaac's ever made was selling 58,400 units of Atara Biotherapeutics Inc stock on 9 July 2018 worth over $2,336,000. On average, Isaac trades about 7,738 units every 12 days since 2014. As of 29 May 2019 Isaac still owns at least 290,687 units of Atara Biotherapeutics Inc stock.

You can see the complete history of Isaac Ciechanover stock trades at the bottom of the page.

What's Isaac Ciechanover's mailing address?

Isaac's mailing address filed with the SEC is 611 Gateway Blvd #900, South San Francisco, CA 94080, USA.

Insiders trading at Atara Biotherapeutics Inc

Over the last 10 years, insiders at Atara Biotherapeutics Inc have traded over $58,305,463 worth of Atara Biotherapeutics Inc stock and bought 1,293,860 units worth $5,821,259 . The most active insiders traders include Joel S Marcus, Eric Dobmeier és Ronald C Jr Renaud. On average, Atara Biotherapeutics Inc executives and independent directors trade stock every 9 days with the average trade being worth of $99,047. The most recent stock trade was executed by Pascal Touchon on 16 August 2024, trading 3,038 units of ATRA stock currently worth $20,142.

What does Atara Biotherapeutics Inc do?

we launched atara biotherapeutics in august 2012 to help patients combat cancer, kidney disease and other illnesses. our research is based on groundbreaking discoveries regarding the ability of activin, myostatin and other growth factors to change the course of disease progression. our goal is to help patients such as atara ciechanover, our company’s namesake, who suffered from cancer before passing away in 2012. we aim to empower patients to fight their illnesses with better treatment options. atara biotherapeutics is developing several innovative product candidates, including pinta 745, stm 434 and ata 842, and is collaborating with memorial sloan kettering cancer center (msk) in the development of three t-cell product candidates: epstein-barr virus (ebv)-targeted cytotoxic t lymphocytes (ctls), cytomegalovirus (cmv)-targeted ctls, and wilms tumor 1 (wt1)-targeted ctls. each product candidate is designed to address the underlying mechanisms of disease to treat conditions which have

Complete history of Isaac Ciechanover stock trades at Atara Biotherapeutics Inc

Atara Biotherapeutics Inc executives and stock owners

Atara Biotherapeutics Inc executives and other stock owners filed with the SEC include:

• Pascal Touchon,
  President, Chief Executive Officer, Director
• Joseph Newell,
  Chief Operating Officer, Executive Vice President
• Utpal Koppikar,
  Chief Financial Officer
• Dr. Pascal Touchon D.V.M.,
  Pres, CEO & Director
• Dr. Kristin Yarema Ph.D.,
  SVP & Chief Commercial Officer
• Joseph Newell,
  Exec. VP & COO
• Utpal Koppikar,
  CFO & SVP
• Dr. Jakob Dupont,
  Head of Global R&D
• Carol Gallagher,
  Lead Independent Director
• Eric Dobmeier,
  Independent Director
• Matthew Fust,
  Independent Director
• Beth Seidenberg,
  Independent Director
• William Heiden,
  Independent Director
• Roy Baynes,
  Independent Director
• Eric Hyllengren,
  Vice President, Investor Relations & Finance
• Maria Roncarolo,
  Director
• Kristin Yarema,
  Chief Commercial Officer
• K. Amar Murugan,
  Senior Vice President, General Counsel
• Ronald Renaud,
  Chairman of the Board
• Amie Krause,
  Chief People Officer
• Kerry Beth Daly,
  Head of Corp. Communications
• K. Amar Murugan,
  Sr. VP & Gen. Counsel
• Dr. Anhco Nguyen,
  Chief Scientific Officer
• Heather D Turner,
  VP, General Counsel & Sec.
• Joel S Marcus,
  Director
• Gad Soffer,
  Chief Operating Officer
• Isaac E. Ciechanover,
  Chief Executive Officer
• Derrell Porter,
  SVP, Head of Global Commercial
• Joe Newell,
  Chief Operations Officer
• Mitchall G. Clark,
  Chief R & QA Officer
• Christopher Haqq,
  Chief Medical Officer
• Mina Kim,
  Senior VP & General Counsel
• Eckard Weber,
  Director
• Viii Associates, L.P.Blair ...,
  
• Perkins Caufield & Byers Xv...,
  
• Partners Viii, L.P.Blair Ja...,
  
• John Mcgrath,
  Chief Financial Officer
• Dietmar Berger,
  Global Head of R&D
• Ameet Mallik,
  
• Jakob Dupont,
  EVP, Head of R&D
• Charlene A. Banard,
  EVP, Chief Technical Officer
• Amar Murugan,
  EVP, Chief Legal Officer
• Jill Henrich,
  EVP, Global Head RA & Quality
• Manher Joshi,
  EVP, Chief Medical Officer
• Anh Co Nguyen,
  President and CEO